Winter is a difficult season for respiratory health. Incidence of respiratory infections such as influenza increase in the colder months, creating a challenge for medical systems and diagnostics alike. The Northern Hemisphere winter bring elevated influenza and other seasonal viruses to many countries that are still facing high infection rates for the novel coronavirus (SARS-CoV-2).
Although these infections can have similar symptoms, treatment and hygiene regimens for SARS-CoV-2 infection, influenza, and other infections are different, which makes it important to distinguish between SARS-CoV-2 infection and other respiratory conditions.
Running multiple tests on each patient is a difficult and expensive endeavor, but tests are now available that can differentiate between SARS-CoV-2 and common respiratory viruses in a single effort.
Thermo Fisher Scientific has launched two new multiplex tests with which users can detect and differentiate from multiple respiratory viruses simultaneously. These are highly accurate, real-time PCR multiplex tests that allows users to expand their testing menu while maintaining low operational costs.
Providing a complete solution for clinical labs, the workflows include the use of Applied Biosystems™ Pathogen Interpretive Software. This software automatically converts genetic analysis data into a readable report, helping to reduce risk of user interpretation error. Each multiplex assay kit uses 4 dyes in a single real-time PCR reaction, containing 1,000 reactions per kit, providing enduring utility from a single purchase. Find out which test kit is available in your region below.
A single test for COVID-19, Flu A/B, and RSV
The Applied Biosystems™ TaqPath™ COVID-19, Flu A/B, RSV Combo Kit is a CE-IVD marked single test that accurately identifies and distinguishes between SARS-CoV-2, Influenza A/B, and respiratory syncytial virus (RSV). This test uses real-time PCR to generate a diagnostic report in less than two hours after RNA extraction. Its targets are the S and N genes of SARS-CoV-2, the matrix genes of influenza A/B, and the N gene / M Gene of RSV A/B. This test is now CE-IVD marked and available in Austria, Bahrain, Belgium, Chile, Croatia, Cyprus, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Jordon, Kuwait, Lebanon, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Oman, Pakistan, Poland, Portugal, Qatar, Romania, Spain, Sweden, Switzerland, UAE, UK. For more information or to request a quote, click here.
For in vitro diagnostic use.
A single test for COVID-19, Flu A, and Flu B
In the United States, a different kit is available for use under US FDA Emergency Use Authorization (EUA) only. The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B Combo Kit is a single test for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B that uses an authorized end-to-end workflow to evaluate up to 94 specimens in approximately three hours. Its targets are the S and N genes of SARS-CoV-2, the matrix gene of influenza A, and the matrix gene of influenza B. This test kit is now available in the United States for use under the Food and Drug Administration’s Emergency Use Authorization. For more information or to request a quote, click here.
For Emergency Use Authorization (EUA) only. For prescription use only. For in vitro diagnostic use.
To explore the growing portfolio of COVID-19 testing solutions from Thermo Fisher, visit us at www.thermofisher.com/covid19